OA13 High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study

Authors :: Jun Liu
Z. Han
M. Zhao
Xiaohui He
W. Su
Shutian Zhang
G. Cheng
Diansheng Zhong
Da Jiang
Li Liang
Jin Wu
Yongyan Wang
X. Hu
Hao Wang
Lei Zhang
Xia Li
Yingze Zhang
Aimin Zang
Chi Zhang
G. An
Cuimin Ding
Source :: Journal of Thoracic Oncology. 13:S1049
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Internal medicine
Icotinib
Medicine
Phases of clinical research
Open label
business
L858r mutation

Full Text Access

Tools